{
    "nct_id": "NCT05012618",
    "official_title": "A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Age >= 18 years at time of signing informed consent form\n* ECOG performance status of 0 or 1\n* Patients with a histologically or cytologically proven diagnosis of a locally advanced, recurrent, or metastatic incurable solid tumor for which standard therapy either does not exist or has proven ineffective or intolerable\n* Patients with documented RAS alterations positive solid tumors\n* Patients with measurable disease per RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), unstable angina, or myocardial infarction within the previous 6 months or unstable arrhythmias within the previous 3 months\n* Patients with primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases\n* Patients with current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular disease, pulmonary disease, or renal disease, ongoing or active infection)\n* Patients with a history or complication of interstitial lung disease (ILD)",
    "miscellaneous_criteria": ""
}